Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (248)	11/7/2001 9:04:53 PM
From: Gary Mohilner	Read Replies (2) \| Respond to of 1022

Ice, While it's not a part of that article, it should be recognized that the majority of the MAB's that MEDX and others can create by themselves may have little or no curative benefits. If you add a toxin, as IMGN, SGEN, and others are working on the drugs you create may have tremendous potential. Take a look at the recent releases from DNA regarding the preclinical results they've gotten from Herceptin-DM1, which they've created through their partnership with IMGN. It's only preclinical, but by this time next year we should have a good idea of how well it does in the clinic. Gary